• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Chimerix, Inc. - Common Stock (NQ:CMRX)

8.540 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chimerix, Inc. - Common Stock

< Previous 1 2 3 Next >
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
July 28, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
March 21, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
March 12, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
March 11, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
March 11, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
March 10, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
March 08, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
March 07, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
March 05, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
March 05, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
March 05, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 05, 2025
From Chimerix, Inc.; Jazz Pharmaceuticals plc
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
February 18, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
January 29, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2025
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Speak Today at The White House Cancer Moonshot Forum
January 13, 2025
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development 
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
December 30, 2024
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility 
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
November 11, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 07, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
November 01, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap